SV Health Investors

Activity in this selectionoxford-innovation-finance-03f5fb23

By stage

Undisclosed2

Series B1

Series C+1

Biotech3

Healthtech1

United States2

Australia1

United Kingdom1

4 in this selection

Jul 15

Develops lead-212 targeted alpha therapies to treat cancer

$315MSeries D

Role not disclosed

Jul 14

Developing transformative, best-in-class neuropsychiatric therapies

$65MSeries B

Role not disclosed

Jan 27

Develops precision immunoregulatory medicines based on tissue Treg biology

$50MUndisclosed

Role not disclosed

Jan 13

Provides healthcare financing and payments solutions

$33MUndisclosed

Role not disclosed